Lilly
4Q Revenues: $6.4 billion (+5%)
4Q Earnings: $1.1 billion (loss of $1.7 billion 4Q17)
FY Revenues: $24.6 billion (+7%)
FY Earnings: $3.2 billion (loss of $204 million FY17)
Comments: Revenue in the U.S. increased 7% to $3.7 billion, driven by increased volume, partially offset by lower realized prices, primarily in the diabetes portfolio. Growth was driven by newer products, including Trulicity, Taltz and Basaglar, partially offset by decreased volume for products that have lost exclusivity, including Cialis and Effient. Revenue outside the U.S. increased 1% to $2.8 billion, driven by increased volume for Trulicity, Olumiant and Taltz, partially offset by decreased volume for Cialis due to loss of exclusivity. In 4Q17, the company recognized asset impairment, restructuring and other special charges of $1 billion, associated with efforts to reduce the company’s cost structure, including the U.S. voluntary early retirement program.